Burosumab-Twza is a medication that has been approved by the FDA for the treatment of X-linked hypophosphatemia (XLH) in adults and children. XLH is a rare genetic disorder that affects the bones and teeth, leading to low levels of phosphate in the blood and resulting in bone deformities, growth retardation, and dental problems.

Burosumab-Twza works by targeting the underlying cause of XLH, which is a mutation in the gene responsible for regulating phosphate levels in the body. By blocking the activity of a protein that inhibits phosphate reabsorption in the kidneys, burosumab-Twza helps to increase phosphate levels in the blood and improve bone mineralization.

Clinical trials have shown that treatment with burosumab-Twza can lead to significant improvements in bone mineral density, growth rates, and overall quality of life for patients with XLH. It is administered as a subcutaneous injection every two weeks, and the dosage is adjusted based on the patient’s weight and response to treatment.

As with any medication, there are potential side effects to be aware of when taking burosumab-Twza. These may include injection site reactions, hypersensitivity reactions, and changes in blood calcium levels. It is important to discuss any concerns or questions with your healthcare provider before starting treatment with burosumab-Twza.

Overall, burosumab-Twza represents a promising new treatment option for patients with XLH, offering the potential to improve bone health and quality of life for those affected by this rare genetic disorder. If you or a loved one has been diagnosed with XLH, talk to your healthcare provider to see if burosumab-Twza may be a suitable treatment option for you.